Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.

Haematologica · 2018 · PMC6029555 · PMID 29674504

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

of borderline significanceno p-value reported

26.8), whereas an advanced stage was of borderline significance (median 20.6 vs . 25.8 months).

also in 2,624 other papers

highly significantno p-value reported

It is noteworthy that a highly significant PFS advantage with the BCL2 inhibitor venetoclax plus rituximab compared to BR has been recently reported in the planned interim analysis of the randomized phase III Murano study, where 42.8% of patients had received 2 or more lines of therapy. 34 However, in this trial, an OS benefit has not yet been shown according to the predefined statistical model.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.